Dexelvucitabine | CAS#134379-77-4 | nucleoside reverse transcriptase inhibitor

MedKoo Cat#: 328058 | Name: Dexelvucitabine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dexelvucitabine, also known as DPC-817; INCB-8721; PSI-5582; YZ-817, DOC-817, is a nucleoside reverse transcriptase inhibitor potentially for the treatment of HIV infection.

Chemical Structure

Dexelvucitabine

CAS#134379-77-4

Theoretical Analysis

MedKoo Cat#: 328058

Name: Dexelvucitabine

CAS#: 134379-77-4

Chemical Formula: C9H10FN3O3

Exact Mass: 227.0706

Molecular Weight: 227.20

Elemental Analysis: C, 47.58; H, 4.44; F, 8.36; N, 18.50; O, 21.13

Price and Availability

Size	Price	Availability
1mg	USD 90.00	Ready to ship
5mg	USD 350.00	Ready to ship
10mg	USD 550.00	Ready to ship
25mg	USD 950.00	Ready to ship
50mg	USD 1,650.00	Ready to ship
100mg	USD 2,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Dexelvucitabine; beta-D-D-4FC; D-D-4FC; DFC; DPC-817; RVT; INCB-8721; PSI-5582; YZ-817; DOC-817. trade name: Reverset.

IUPAC/Chemical Name

4-amino-5-fluoro-1-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1H)-one

InChi Key

HSBKFSPNDWWPSL-CAHLUQPWSA-N

InChi Code

InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1

SMILES Code

OC[C@@H]1C=C[C@H](N2C(N=C(C(F)=C2)N)=O)O1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# B22B02C28

QC Data

View QC data: current batch, Lot# B22B02C28

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Dexelvucitabine (Reverset), a cytidine analog, is a nucleoside reverse transcriptase inhibitor against HIV-1-resistant viruses containing a thymidine analog and/or M184V mutation in the viral polymerase. Dexelvucitabine is a 2’-deoxycytidine antiretroviral agent.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 227.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Meusinger R. Doubling spectroscopy challenge. Anal Bioanal Chem. 2015 Nov;407(27):8169-72. doi: 10.1007/s00216-015-9002-x. PubMed PMID: 26463052. 2: Schinazi RF, Massud I, Rapp KL, Cristiano M, Detorio MA, Stanton RA, Bennett MA, Kierlin-Duncan M, Lennerstrand J, Nettles JH. Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase. Antimicrob Agents Chemother. 2011 May;55(5):2054-60. doi: 10.1128/AAC.01700-10. PubMed PMID: 21357304; PubMed Central PMCID: PMC3088218. 3: Elvucitabine data released at CROI. AIDS Patient Care STDS. 2010 Mar;24(3):198. PubMed PMID: 20235383. 4: Colucci P, Pottage JC, Robison H, Turgeon J, Ducharme MP. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother. 2009 Feb;53(2):646-50. doi: 10.1128/AAC.00905-08. PubMed PMID: 19015353; PubMed Central PMCID: PMC2630647. 5: Colucci P, Pottage JC, Robison H, Turgeon J, Schürmann D, Hoepelman IM, Ducharme MP. Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrob Agents Chemother. 2009 Feb;53(2):662-9. doi: 10.1128/AAC.00907-08. PubMed PMID: 19015343; PubMed Central PMCID: PMC2630663. 6: Hernandez-Santiago BI, Mathew JS, Rapp KL, Grier JP, Schinazi RF. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007 Jun;51(6):2130-5. PubMed PMID: 17403996; PubMed Central PMCID: PMC1891415. 7: dD4FC development discontinued. AIDS Clin Care. 2006 May;18(5):47. PubMed PMID: 16718907. 8: Feinberg J. Meeting notes from the 3rd IAS Conference. New drugs. AIDS Clin Care. 2005 Oct;17(10):96-7. PubMed PMID: 16276591. 9: Susman E. HIV Pathogenesis and Treatment - Third International AIDS Society Conference. IDrugs. 2005 Oct;8(10):813-5. PubMed PMID: 16254799. 10: Hammond JL, Parikh UM, Koontz DL, Schlueter-Wirtz S, Chu CK, Bazmi HZ, Schinazi RF, Mellors JW. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrob Agents Chemother. 2005 Sep;49(9):3930-2. PubMed PMID: 16127074; PubMed Central PMCID: PMC1195387. 11: Waters L, Nelson MR. New drugs. HIV Med. 2005 Jul;6(4):225-31. Review. PubMed PMID: 16011526. 12: Sax PE. Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients. AIDS Clin Care. 2005 Jan;17(1):8. PubMed PMID: 15717377. 13: Stuyver LJ, McBrayer TR, Schürmann D, Kravec I, Beard A, Cartee L, Schinazi RF, De La Rosa A, Murphy RL, Otto MJ. Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose. Antivir Ther. 2004 Aug;9(4):529-36. PubMed PMID: 15456084. 14: Otto MJ. New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr Opin Pharmacol. 2004 Oct;4(5):431-6. Review. PubMed PMID: 15351346. 15: Painter GR, Almond MR, Mao S, Liotta DC. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. Curr Top Med Chem. 2004;4(10):1035-44. Review. PubMed PMID: 15193137. 16: Sagir A, Avci A, Erhardt A, Lörke J, Heintges T, Häussinger D. [New approaches in the treatment of hepatitis B]. Dtsch Med Wochenschr. 2004 May 21;129(21):1203-8. Review. German. PubMed PMID: 15160325. 17: James JS. Antiretroviral pipeline: new-drug reports from retroviruses conference. AIDS Treat News. 2004 Feb 27;(398):1-2. PubMed PMID: 15119288. 18: Murakami E, Ray AS, Schinazi RF, Anderson KS. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 2004 Apr;62(1):57-64. PubMed PMID: 15026203. 19: Shi J, Mathew JS, Tharnish PM, Rachakonda S, Pai SB, Adams M, Grier JP, Gallagher K, Zhang H, Wu JT, Shi G, Geleziunas R, Erickson-Viitanen S, Stuyver L, Otto MJ, Watanabe KA, Schinazi RF. N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity. Antivir Chem Chemother. 2003 Mar;14(2):81-90. PubMed PMID: 12856919. 20: Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset). Antivir Chem Chemother. 2003 Jan;14(1):49-59. PubMed PMID: 12790516.